Updates to Polymyalgia Rheumatica Care: Sarilumab Insights
Dana McCormick, R.Ph., and Robert Spiera, M.D., delve into the SAPHYR trial, discussing sarilumab’s role in managing polymyalgia rheumatica relapse during glucocorticoid tapers.
This is a video synopsis/summary of a Between the Lines involving Robert Spiera, M.D., and Dana McCormick, R.Ph.
Robert Spiera, M.D., highlights the initial success of steroid therapy, yet the prolonged use poses significant challenges due to side effects. Patients, especially older individuals with comorbidities, face increased vulnerability to steroid-related toxicity, with up to 65% experiencing notable side effects. Managing polymyalgia rheumatica evolves from the initial relief to the long-term impact of steroid-related complications.
He emphasizes the dilemma: Extended steroid use addresses polymyalgia rheumatica symptoms but exacerbates health risks. Without an alternative to control disease activity, patients face functional limitations. The discussion underscores the critical need for new therapies like sarilumab to address polymyalgia rheumatica relapse during glucocorticoid tapers, offering hope for improved disease management while mitigating steroid-related challenges in long-term treatment.
This summary was AI-generated and reviewed by Managed Healthcare Executive® staff.
